BeStock  
Stocks › Biotechnology › MRVI

Maravai LifeSciences MRVI

US equityMarket cap rank #3127Biotechnology
$6.98 −$0.21 (-2.92%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $6.98 0.00%
Open$7.06
Prev close$7.19
Day range$6.91 – $7.17
Volume1.79M
Market cap$1.04B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$45.85M+10.1% YoY
Operating profit-$17.70M+47.4% YoY
Net profit-$24.00M+46.7% YoY
Diluted EPS-$0.09+50.0% YoY
Free cash flow$4.49M+124.9% YoY
Operating cash flow$5.02M

Revenue, last 8 quarters

$56.6MDec '24$46.9MMar '25$47.4MJun '25$41.6MSep '25$49.9MDec '25$65.8MMar '26$51.4MJun '26$45.9MSep '26

Net profit, last 8 quarters

$-46.1MDec '24$-52.9MMar '25$-69.8MJun '25$-45.1MSep '25$-63.0MDec '25$-6.4MMar '26$-21.6MJun '26$-24.0MSep '26

Diluted EPS by quarter

-0.18Dec '24-0.21Mar '25-0.27Jun '25-0.18Sep '25-0.24Dec '25-0.02Mar '26-0.08Jun '26-0.09Sep '26

Free cash flow by quarter

$-19.5MDec '24$-13.9MMar '25$-13.1MJun '25$-18.1MSep '25$-25.6MDec '25$4.2MMar '26$3.6MJun '26$4.5MSep '26

Annual revenue

$284.1MFY20$799.2MFY21$883.0MFY22$288.9MFY23$259.2MFY24$185.7MFY25

Profitability & balance sheet

Gross margin39.1%
Operating margin-25.6%
Net margin-30.8%
Return on equity-29.8%
Return on assets-9.1%
Return on invested capital-10.3%
Current ratio4.66
Liabilities / assets43.3%
Cash & investments$73.02M
Total debt$176.48M
Net cash (debt)-$103.45M

Where the revenue comes from

Quarter 2026/Q3

By business line

  • TriLink$28.35M 61.8%
  • Cygnus$17.50M 38.2%

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $45.85M $51.44M $65.84M $185.74M $49.87M
Total Operating Revenue $45.85M $51.44M $65.84M $185.74M $49.87M
Cost of Revenue $29.66M $30.79M $32.14M $151.75M $37.02M
Gross Profit $16.19M $20.65M $33.70M $33.99M $12.84M
Operating Expense $33.89M $35.77M $32.98M $162.52M $35.17M
Selling and Admin Expenses $30.50M $32.07M $29.09M $145.12M $31.38M
Research & Development $3.39M $3.70M $3.89M $17.40M $3.79M
Operating Profit -$17.70M -$15.12M $720,000.00 -$128.53M -$22.33M
Net Non-Operating Interest Income (Expense) -$3.43M -$3.65M -$3.88M -$15.56M -$4.17M
Non-Operating Interest Income $598,000.00 $1.16M $1.87M $11.44M $2.38M
Non-Operating Interest Expense $4.03M $4.81M $5.75M $26.99M $6.56M
Other Income (Expense) -$2.95M -$3.03M -$3.37M -$90.89M -$36.51M
Special Income (Charges) -$2.92M -$2.98M -$2.88M -$86.74M -$36.47M
-Less:Restructuring and Mergern & Acquisition $2.92M -$33,000.00 $2.88M $18.03M $10.64M
-Less:Impairment of Capital Assets $0.00 $0.00 $0.00 $68.71M $25.83M
Other Non-Operating Income (Expenses) -$27,000.00 -$52,000.00 -$494,000.00 -$4.15M -$43,000.00
Pretax Profit -$24.08M -$21.80M -$6.53M -$234.97M -$63.01M
Tax -$75,000.00 -$171,000.00 -$151,000.00 -$4.21M $6,000.00
Net Profit -$24.00M -$21.63M -$6.38M -$230.76M -$63.02M
Profit from Continuing Operations -$24.00M -$21.63M -$6.38M -$230.76M -$63.02M
Minority Interests -$10.16M -$9.22M -$2.64M -$99.99M -$27.33M
Net Income to Parent Company -$13.84M -$12.42M -$3.73M -$130.77M -$35.68M
Net Income to Common Stockholders -$13.84M -$12.42M -$3.73M -$130.77M -$35.68M
Basic EPS -$0.09 -$0.08 -$0.02 -$0.90 -$0.24
Diluted EPS -$0.09 -$0.08 -$0.02 -$0.90 -$0.24
-Less:Other Special Charges – $3.01M – – –

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $600.07M $603.75M $713.22M $770.58M $770.58M
Total Current Assets $154.00M $155.66M $251.74M $296.25M $296.25M
Cash and Cash Equivalents & Short-Term Investments $73.02M $70.09M $165.92M $216.89M $216.89M
-Cash and Cash Equivalents $73.02M $70.09M $165.92M $216.89M $216.89M
Receivables $25.71M $31.14M $33.42M $25.50M $25.50M
-Accounts Receivable $25.71M $31.14M $33.42M $25.50M $25.50M
Inventory $43.25M $41.23M $40.46M $40.50M $40.50M
Other Current Assets $12.02M $13.20M $11.94M $13.37M $13.37M
Total Non-Current Assets $446.07M $448.09M $461.48M $474.33M $474.33M
Net PPE $135.67M $142.41M $146.93M $190.74M $190.74M
-Gross PPE $135.67M $142.41M $146.93M $258.82M $258.82M
Goodwill and Other Intangible Assets $260.40M $267.80M $274.32M $280.97M $280.97M
-Goodwill $129.43M $129.43M $129.43M $129.43M $129.43M
-Other Intangible Assets $130.97M $138.38M $144.89M $151.54M $151.54M
Other Non-Current Assets $50.00M $37.87M $40.24M $2.62M $2.62M
Total Liabilities $259.90M $248.16M $344.13M $397.87M $397.87M
Total Current Liabilities $33.06M $38.42M $42.62M $44.92M $44.92M
Payables $6.48M $7.13M $8.54M $3.65M $3.65M
-Accounts Payable $6.48M $7.13M $8.54M $2.91M $2.91M
Current Accrued Expenses $25.08M $30.17M $28.65M $11.08M $11.08M
Short-Term Debt and Capital Lease Obligation $1.50M $1.13M $5.44M $14.20M $14.20M
-Current Debt $1.50M $1.13M $5.44M $5.44M $5.44M
Total Non-Current Liabilities $226.84M $209.74M $301.51M $352.95M $352.95M
Long Term Debt and Capital Lease Obligation $174.98M $175.57M $265.44M $350.51M $350.51M
-Long Term Debt $145.68M $145.98M $235.57M $286.33M $286.33M
-Long Term Capital Lease Obligation $29.30M $29.59M $29.87M $64.18M $64.18M
Other Non-Current Liabilities $51.86M $34.17M $36.07M $197,000.00 $197,000.00
Total Equity $340.17M $355.59M $369.08M $372.71M $372.71M
Stockholders' Equity $195.89M $204.62M $211.56M $212.38M $212.38M
Capital Stock $2.60M $2.60M $2.58M $2.56M $2.56M
-Common Stock $2.60M $2.60M $2.58M $2.56M $2.56M
Additional Paid-In Capital $212.70M $207.60M $202.13M $199.18M $199.18M
Retained Earnings -$19.87M -$6.03M $6.39M $10.12M $10.12M
Gains/Losses Not Affecting Retained Earnings $456,000.00 $459,000.00 $466,000.00 $524,000.00 $524,000.00
Minority Interests $144.28M $150.97M $157.52M $160.33M $160.33M
-Accumulated Depreciation – – – -$68.08M -$68.08M
-Total Tax Payable – – – $742,000.00 $742,000.00
-Current Capital Lease Obligation – – – $8.76M $8.76M
Current Deferred Liabilities – – – $2.99M $2.99M
Other Current Liabilities – – – $1.89M $1.89M
Long Term Accounts Payable and Other Payables – – – $0.00 $0.00
Non-Current Accrued Expenses – – – $0.00 $0.00
Non-Current Deferred Liabilities – – – $2.25M $2.25M

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow $5.02M $3.99M $8.67M -$57.57M -$22.77M
Net cash flow from continuing operations $5.02M $3.99M $8.67M -$57.57M -$22.77M
Net Income from Continuing Operations -$24.00M -$21.63M -$6.38M -$230.76M -$63.02M
Gain/Loss from Continuing Operations $0.00 – – – –
Depreciation & Depletion & Amortization $13.85M $13.41M $12.98M $60.47M $14.73M
Deferred Tax $0.00 – – $4.06M -$20,000.00
Other Non-Cash Items $51,000.00 -$340,000.00 $541,000.00 $1.87M $657,000.00
Change in Working Capital $2.96M -$926,000.00 -$5.83M -$7.98M -$19.43M
-Change in Receivables $5.44M $2.29M -$7.91M $12.82M -$2.96M
-Change in Inventory -$2.02M -$768,000.00 $33,000.00 $8.00M $3.09M
-Change in Prepaid Assets $1.18M -$771,000.00 $1.43M $1.63M $1.18M
-Change in Payables and Accrued Expense -$5.54M $15,000.00 $826,000.00 -$11.97M -$19.03M
-Change in Other Current Liabilities $3.90M -$1.69M -$203,000.00 -$18.63M -$1.89M
Net cash flow from investing -$523,000.00 -$370,000.00 -$4.44M -$31.41M -$2.11M
Net Cash Flow from Continuing Investing Activities -$523,000.00 -$370,000.00 -$4.44M -$31.41M -$2.11M
Net PPE Purchase and Sale -$523,000.00 -$370,000.00 -$4.44M -$12.42M -$2.11M
Net Business Purchase and Sale $0.00 $0.00 $0.00 -$18.99M $0.00
Financing Cash Flow -$1.57M -$98.98M -$55.23M -$16.50M -$1.82M
Net Cash Flow from Continuing Financing Activities -$1.57M -$98.98M -$55.23M -$16.50M -$1.82M
Net Issuance Payments Of Debt $0.00 -$92.88M -$51.36M -$5.44M -$1.36M
Proceeds from Stock Option Exercised -$1.33M – – – –
Net Other Financing Charges -$244,000.00 -$164,000.00 -$3.87M -$11.06M -$5.06M
Ending Cash Balance $73.51M $70.58M $165.92M $216.89M $216.89M
Net Change in Cash $2.92M -$95.36M -$51.00M -$105.48M -$26.70M
Beginning Cash Balance $70.58M $165.92M $216.89M $322.40M $243.57M
Effect of Exchange Rate Changes $10,000.00 $17,000.00 $30,000.00 -$32,000.00 $14,000.00
Free Cash Flow $4.49M $3.62M $4.23M -$70.72M -$25.62M
-Change in Other Current Assets – – – $181,000.00 –

Discussion

No comments yet — be the first to weigh in on MRVI.

Sign in to join the discussion.

Scroll to Top